scholarly journals Why is the prostate cancer death rate declining in the united states?

Cancer ◽  
1998 ◽  
Vol 82 (2) ◽  
pp. 249-251 ◽  
Author(s):  
Curtis J. Mettlin ◽  
Gerald P. Murphy
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Death Rate ◽  
The United States ◽  
Cancer Death ◽  
Cancer Death Rate ◽  
Prostate Cancer Death

scholarly journals Application of Neutrosophic Logic to Evaluate Correlation between Prostate Cancer Mortality and Dietary Fat Assumption

Symmetry ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 330 ◽  
Author(s):  
Muhammad Aslam ◽  
Mohammed Albassam
Keyword(s):  
Prostate Cancer ◽  
Dietary Fat ◽  
Death Rate ◽  
Prostate Cancer Risk ◽  
Cancer Death ◽  
Classical Statistics ◽  
Cancer Death Rate ◽  
Prostate Cancer Death ◽  
Fat Level ◽  
Uncertainty Environment

This paper presents an epidemiological study on the dietary fat that causes prostate cancer in an uncertainty environment. To study this relationship under the indeterminate environment, data from 30 countries are selected for the prostate cancer death rate and dietary fat level in the food. The neutrosophic correlation and regression line are fitted on the data. We note from the neutrosophic analysis that the prostate cancer death rate increases as the dietary fat level in the people increases. The neutrosophic regression coefficient also confirms this claim. From this study, we conclude that neutrosophic regression is a more effective model under uncertainty than the regression model under classical statistics. We also found a statistical correlation between dietary fat and prostate cancer risk.

State rurality does not increase risk of prostate cancer death.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 119-119
Author(s):  
Alexander Geoffrey Shaw Anderson ◽  
Katie Murray
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Rural Communities ◽  
Death Rate ◽  
Prostate Cancer Screening ◽  
Cancer Death ◽  
Psa Screening ◽  
The Us ◽  
Cancer Death Rate ◽  
Prostate Cancer Death

119 Background: Prostate cancer is the third most common cancer among men. PSA based screening for prostate cancer was introduced in the 1980s and resulted in a significant decline in prostate cancer mortality. Current AUA guidelines recommend PSA screening in average risk patients between the ages of 55 and 69. There are public health concerns in rural areas of the United States (US) potentially due to decreased access of care. In this study, we sought to evaluate the prevalence of prostate cancer screening and death rate in rural communities within the US. Methods: After IRB approval, data was collected from several different sources. Annual prostate cancer death rate (2011-2015) was obtained from the American Cancer Society. Data from the Behavioral Risk Factor Surveillance System regarding prostate cancer screening during this time interval was acquired. Data regarding populations was obtained from the US Census. Descriptive analyses were used to describe the population and Pearson Correlation Coefficient to determine screened, death rates and rurality correlations. All analyses were completed using SPSS. Results: The median percent of US population residing in rural and urban areas was 25.8% (IQR 22.1%) and 73.8% (IQR 22.1%), respectively. The median percent of male patients screened using PSA 50 years and older was 56.2% (IQR 7.0%). The median death rate (per 100,000) from prostate cancer per state was 19.5 (IQR 1.7%). Prostate cancer death rate was found to have no correlation to percent of population screened (p = 0.29) and percent rurality (p = 0.98). The percent rural population versus percent of screened men over the age of 50 was also not significant (p = 0.20). Conclusions: Neither death rate nor screening rate for prostate cancer using PSA demonstrated a significant association with the percent of patient’s living in rural communities. This is evidence that within the US, rural communities are following guidelines for PSA screening for prostate cancer and therefore there is no discrepancy in prostate cancer death in these areas compared to urban. This study is evidence that the barriers that may be associated with living in rural communities, such as decreased access to healthcare do not translate into worse outcomes related to prostate cancer.

2243 COMBINED VALUE OF GENOMIC BIOMARKERS AND CAPRA-S IN PREDICTING PROSTATE CANCER DEATH IN A HIGH-RISK SURGICAL COHORT

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Matthew Cooperberg ◽  
Anamaria Crisan ◽  
Anirban Mitra ◽  
Mercedeh Ghadessi ◽  
Christine Buerki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Death ◽  
Genomic Biomarkers ◽  
Prostate Cancer Death

The Opioid Epidemic and Homicide in the United States

2021 ◽  
pp. 002242782098684
Author(s):  
Richard Rosenfeld ◽  
Joel Wallman ◽  
Randolph Roth
Keyword(s):  
United States ◽  
Death Rate ◽  
The United States ◽  
Opioid Epidemic ◽  
Drug Markets ◽  
Cross Sectional ◽  
Homicide Rates ◽  
Overdose Death ◽  
Sectional Analysis ◽  
The Relationship

Objectives: Evaluate the relationship between the opioid epidemic and homicide rates in the United States. Methods: A county-level cross-sectional analysis covering the period 1999 to 2015. The race-specific homicide rate and the race-specific opioid-related overdose death rate are regressed on demographic, social, and economic covariates. Results: The race-specific opioid-related overdose death rate is positively associated with race-specific homicide rates, net of controls. The results are generally robust across alternative samples and model specifications. Conclusions: We interpret the results as reflecting the violent dynamics of street drug markets, although more research is needed to draw definitive conclusions about the mechanisms linking opioid demand and homicide.

scholarly journals Racial Differences in Incident Genitourinary Cancer Cases Captured in the National Cancer Database

Medicina ◽  
2021 ◽  
Vol 57 (7) ◽  
pp. 671
Author(s):  
Dylan T. Wolff ◽  
Thomas F. Monaghan ◽  
Danielle J. Gordon ◽  
Kyle P. Michelson ◽  
Tashzna Jones ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Bladder Cancer ◽  
Kidney Cancer ◽  
The United States ◽  
Coverage Rate ◽  
National Cancer Database ◽  
Genitourinary Cancer ◽  
Coverage Rates ◽  
Capture Rates

Background and Objectives: The National Cancer Database (NCDB) captures nearly 70% of all new cancer diagnoses in the United States, but there exists significant variation in this capture rate based on primary tumor location and other patient demographic factors. Prostate cancer has the lowest coverage rate of all major cancers, and other genitourinary malignancies likewise fall below the average NCDB case coverage rate. We aimed to explore NCDB coverage rates for patients with genitourinary cancers as a function of race. Materials and Methods: We compared the incidence of cancer cases in the NCDB with contemporary United States Cancer Statistics data. Results: Across all malignancies, American Indian/Alaskan Natives subjects demonstrated the lowest capture rates, and Asian/Pacific Islander subjects exhibited the second-lowest capture rates. Between White and Black subjects, capture rates were significantly higher for White subjects overall and for prostate cancer and kidney cancer in White males, but significantly higher for bladder cancer in Black versus White females. No significant differences were observed in coverage rates for kidney cancer in females, bladder cancer in males, penile cancer, or testicular cancer in White versus Black patients. Conclusions: Differential access to Commission on Cancer-accredited treatment facilities for racial minorities with genitourinary cancer constitutes a unique avenue for health equity research.

scholarly journals Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

2021 ◽  
Author(s):  
A. I. Peltomaa ◽  
P. Raittinen ◽  
K. Talala ◽  
K. Taari ◽  
T. L. J. Tammela ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Cancer Prognosis ◽  
Cancer Death ◽  
Psa Relapse ◽  
Prostate Cancer Death ◽  
Study Population ◽  
Statin Use ◽  
Prostate Cancer Prognosis

Abstract Purpose Statins’ cholesterol-lowering efficacy is well-known. Recent epidemiological studies have found that inhibition of cholesterol synthesis may have beneficial effects on prostate cancer (PCa) patients, especially patients treated with androgen deprivation therapy (ADT). We evaluated statins’ effect on prostate cancer prognosis among patients treated with ADT. Materials and methods Our study population consisted of 8253 PCa patients detected among the study population of the Finnish randomized study of screening for prostate cancer. These were limited to 4428 men who initiated ADT during the follow-up. Cox proportional regression model adjusted for tumor clinical characteristics and comorbidities was used to estimate hazard ratios for risk of PSA relapse after ADT initiation and prostate cancer death. Results During the median follow-up of 6.3 years after the ADT initiation, there were 834 PCa deaths and 1565 PSA relapses in a study cohort. Statin use after ADT was associated with a decreased risk of PSA relapse (HR 0.73, 95% CI 0.65–0.82) and prostate cancer death (HR 0.82; 95% CI 0.69–0.96). In contrast, statin use defined with a one-year lag (HR 0.89, 95% CI 0.76–1.04), statin use before ADT initiation (HR 1.12, 95% CI 0.96–1.31), and use in the first year on ADT (HR 1.02, 95% CI 0.85–1.24) were not associated with prostate cancer death, without dose dependency. Conclusion Statin use after initiation of ADT, but not before, was associated with improved prostate cancer prognosis.

Sign in / Sign up

Export Citation Format

Share Document